Tissue-Based Genomic Testing in Prostate Cancer: 10-Year Analysis of National Trends on the Use of Prolaris, Decipher, ProMark, and Oncotype DX

CONCLUSIONS: Our analysis indicates a growing trend in the utilization of tissue-based genomic testing for PCa. Nevertheless, they are utilized in less than 2% of PCa patients, whether at initial diagnosis or after surgical treatment. Although it is anticipated that their use may increase as more scientific evidence becomes available, their role requires further elucidation.PMID:38525718 | PMC:PMC10961791 | DOI:10.3390/clinpract14020039

Source: Clinical Prostate Cancer - March 25, 2024 Category: Cancer & Oncology Authors: Eugenio Bologna Francesco Ditonno Leslie Claire Licari Antonio Franco Celeste Manfredi Spencer Mossack Savio Domenico Pandolfo Cosimo De Nunzio Giuseppe Simone Costantino Leonardo Giorgio Franco Source Type: research